• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Related Topics

  1. USAA Large Value
  2. USAA Large Growth
  3. Dendreon Corporation
  4. USAA Large Blend
  5. Eli Lilly
  6. Pfizer

Popular Topics

  1. Eagle Bulk Shipping
  2. Commercial Banks
  3. Emerging Markets
  4. European Union
  5. Interest Rate

Merck

Merck & Co Inc MRK 3 Star

Last Price$46.71Day Change (%)-1.31%
Open Price$47.60Day Change ($)-0.62
Day Range46.49–48.3052-Week Range37.02–48.79

As of Thu 05/23/2013 03:15 AM EDT | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck Unveils $5 Billion Accelerated Share Buyback

    Merck Unveils $5 Billion Accelerated Share Buyback

  2. Merck to Present at the UBS Global Healthcare Conference

    Merck to Present at the UBS Global Healthcare Conference

  3. Merck KGaA to Reach 2014 Outlook One Year Early, 1Q Profit Up

    Merck KGaA to Reach 2014 Outlook One Year Early, 1Q Profit Up

  4. Pfizer to Spin Off Remaining Zoetis Stake

    Pfizer to Spin Off Remaining Zoetis Stake

  5. Merck Consumer Care Launches Health and Wellness Effort To Help Empower Moms To Live A More Active Lifestyle With Their Families

    Merck Consumer Care Launches Health and Wellness Effort To Help Empower Moms To Live A More Active Lifestyle With Their Families

  6. Research and Markets: Global Vaccine Market Forecast to 2017

    Research and Markets: Global Vaccine Market Forecast to 2017

  7. Research and Markets: PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

    Research and Markets: PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

  8. Merck MRK Q4 2012 Earnings Call Transcript

    Good day, everyone, and welcome to Merck's Fourth Quarter 2012 Earnings Conference Call. Today's call is being recorded.

  9. Fitch Rates Merck & Co.'s Proposed Debt 'A+'

    Fitch Rates Merck & Co.'s Proposed Debt 'A+'

  10. Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver ...

    Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™

12345…
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.